Traws Pharma defers Phase 2a influenza study after MHRA regulatory review
Traws Pharma deferred its planned Phase 2a human influenza challenge study for tivoxavir marboxil (TXM) following a negative regulatory review by the UK's MHRA, citing mutagenic concerns. The company is advancing backup antiviral candidates with similar pharmacokinetic profiles while maintaining cash runway through Q1 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day